间质上皮细胞转化因子抑制剂特泊替尼的临床研究进展

Clinical research progress of mesenchymal-epithelial transition factor inhibitor tepotinib

间质上皮细胞转化因子(mesenchymal-epithelial transition factor,MET)是非小细胞肺癌(non-small cell lung cancer,NSCLC)的一种重要肿瘤驱动基因。近年来,针对MET信号传导通路的靶向治疗成为了肺癌治疗的新靶点。特泊替尼作为全球首个口服、高选择性、强效MET抑制剂,先后在日本和美国被批准用于不可切除、MET外显子14跳跃突变的晚期或复发性NSCLC患者的治疗,同时其在临床研究中亦表现出良好的安全性和有效性。该文主要对目前特泊替尼药物在NSCLC、肝癌及NSCLC伴脑转移等适应证的临床研究进行综述。

Mesenchymal-epithelial transition factor(MET) is an important tumor driver gene in non-small cell lung cancer(NSCLC).In recent years,targeted therapy for MET signaling pathway has become a new target for lung cancer treatment.As the world’s first oral,highly selective and potent MET inhibitor,tepotinib has been approved by Japan and the United States FDA for the treatment of advanced or recurrent NSCLC patients with unresectable and MET exon 14 skipping mutations.At the same time,it has shown good safety and efficacy in clinical studies.This article mainly reviewed the current clinical studies of tepotinib in NSCLC,liver cancer,NSCLC with brain metastasis and so on.